Sophia Genetics SA

AstraZeneca has entered a global partnership with SOPHiA GENETICS to develop and launch two decentralized companion diagnostics in precision oncology. The multi-year collaboration focuses on clinical trial assays that support the development and commercialization of AstraZeneca's oncology therapies, aiming to expand access to personalized cancer treatments by enabling decentralized testing across a wider range of clinical settings. The agreement gives AstraZeneca access to SOPHiA GENETICS's decentralized Solid Tumor and Hematological Oncology diagnostic platforms for use as companion diagnostics, linking its oncology drugs directly to assays that can run in more hospitals rather than only central labs. This can support uptake of existing and future cancer therapies where treatment decisions rely on accurate biomarker testing, and ties real-world data generation more tightly to its portfolio. The partnership fits AstraZeneca's narrative around oncology approvals, late-stage assets, and use of data and technology to support precision medicine, and follows other alliances like Pathos AI.

Several biotech stocks reached 52-week highs on Tuesday, driven by second-quarter earnings reports and regulatory milestones. UFP Technologies surged over 25% to $338.70 after reporting net income of $20.9 million on a 15.1% sales increase to $174 million. InfuSystem Holdings climbed over 33% to $12.49 as second-quarter revenue rose 2.6% to $36.9 million, with Patient Services revenue up 15% offsetting a 16% decline in Device Solutions. SOPHiA Genetics gained over 20% to $6.98 following a 27% revenue jump to $23.3 million, fueled by 64% growth in the U.S. market. Replimune Group touched $13.86 intraday after a favorable advisory committee opinion on its RP1 BLA, though the FDA's August 2 response deadline passed without an update. Parabilis Medicines rose over 5% to $36.69, its highest since its June 11 IPO that raised $770.5 million.

Several biotech stocks reached 52-week highs on July 20, 2026, driven by upcoming clinical trial launches and data readouts. Xencor Inc. hit $20.26, closing up 7%, as it advances XmAb942 in a Phase 2b ulcerative colitis trial with interim results expected by year-end 2026, and two bispecific antibodies in Phase 1 with data due in the second half of 2026. Hemab Therapeutics Holdings Inc. reached $52.15 after reporting positive Phase 2 data for Sutacimig in Glanzmann thrombasthenia and Factor VIII deficiency, showing an 84% reduction in mean annualized treated bleeding rate, along with positive interim Phase 2 results for HMB-002 in Von Willebrand's disease and the launch of HMB-003 for heavy menstrual bleeding. Monopar Therapeutics Inc. hit $115 following positive Phase 3 results for ALXN1840 in Wilson disease, for which it received a Rare Pediatric Disease voucher and plans an NDA submission by mid-2026, while also advancing MNPR-101 in Phase 1 for solid tumors. SOPHiA GENETICS SA rose over 7% to a 52-week high of $6.50, reporting first-quarter revenue of $21.7 million, up 22% year-over-year, and guiding for full-year 2026 revenue of $92 million to $94 million, representing 20% to 22% growth. Aclaris Therapeutics Inc. is advancing Bosakitug in a Phase 2 atopic dermatitis trial with topline results expected in the fourth quarter of 2026, ATI-052 in a Phase 1b for atopic dermatitis and a Phase 2b asthma program starting in the fourth quarter, and ATI-2138 in a planned Phase 2 basket study for lichen planus in the second half of 2026.

SOPHiA GENETICS SA has closed a $57 million public offering of ordinary shares. The offering was oversubscribed, and underwriters fully exercised their option to purchase an additional 1,578,900 shares at the offering price. In total, the company sold 12,104,900 ordinary shares at $4.75 per share. TD Cowen acted as lead book-running manager, with Guggenheim Securities as book-running manager and BTIG and Craig-Hallum as lead managers.